SRR1359171
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.439
- TNFA_SIGNALING_VIA_NFKB+0.435
- KRAS_SIGNALING_DN+0.430
- MYOGENESIS+0.414
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.368
- COAGULATION+0.348
- ESTROGEN_RESPONSE_LATE+0.345
- IL6_JAK_STAT3_SIGNALING+0.342
- INFLAMMATORY_RESPONSE+0.331
- ANGIOGENESIS+0.319
Top 10 suppressed
- MYC_TARGETS_V1-0.571
- PROTEIN_SECRETION-0.500
- MYC_TARGETS_V2-0.495
- E2F_TARGETS-0.455
- G2M_CHECKPOINT-0.442
- DNA_REPAIR-0.426
- MITOTIC_SPINDLE-0.399
- UNFOLDED_PROTEIN_RESPONSE-0.387
- OXIDATIVE_PHOSPHORYLATION-0.322
- MTORC1_SIGNALING-0.291
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1383059 | GTEX | — | 0.949 |
| 2 | SRR1316392 | GTEX | — | 0.945 |
| 3 | SRR1337412 | GTEX | — | 0.945 |
| 4 | SRR1335707 | GTEX | — | 0.932 |
| 5 | SRR1341387 | GTEX | — | 0.931 |
| 6 | SRR1491293 | GTEX | — | 0.931 |
| 7 | R77 | — | — | 0.931 |
| 8 | MNG229 | — | — | 0.925 |
| 9 | BS_044XZ8ST | pilocytic astrocytoma | — | 0.923 |
| 10 | BS_7XRN3CFX | low-grade glioma | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.439 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.435 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.430 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.414 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.368 | Inavolisib | — uncovered |
| COAGULATION | 0.348 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.345 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.342 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.331 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.319 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.308 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.288 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.254 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.226 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.213 | Idelalisib | — uncovered |
| APOPTOSIS | 0.212 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.207 | Inavolisib | — uncovered |
| HYPOXIA | 0.206 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.202 | Idelalisib | — uncovered |